Boston Scientific Corporation (BSX)

Boston Scientific's stock has experienced several notable events and movements in the past six months. In Q1 2025, the company reported revenue of $4.66 billion and adjusted EPS of $0.75, exceeding analyst estimates. In Q2 2025, Boston Scientific surpassed expectations again, reporting revenue of $5.06 billion and adjusted EPS of $0.75. The company received FDA approval for expanded labeling of its FARAPULSE™ Pulsed Field Ablation System in July 2025. Boston Scientific announced the acquisition of Elutia's BioEnvelope Business for $88 million in September 2025. Over the last 12 months, the stock price increased by 15.94%, with a year-to-date return of 9.21%, but decreased by 7.59% in the past month. Several analyst firms have reiterated or raised their price targets for BSX, maintaining "Buy" or "Outperform" ratings.

The medical devices industry, in which Boston Scientific operates, generally experiences steady demand, driven by recurring revenue streams, an aging global population, and advances in digital health. While the industry benefits from these consistent demand drivers, it also faces headwinds from pricing and reimbursement pressures. Specific seasonal patterns are not explicitly detailed, but the underlying demand for medical devices is generally stable and growing due to demographic and technological factors.

Boston Scientific Corporation (BSX) is a global leader in the development, manufacturing, and marketing of less-invasive medical devices. The company operates within the Health Technology sector and the Medical Specialties or Medical/Dental Instruments industry, providing a broad portfolio of innovative products, technologies, and services across various medical specialties. Its major product segments include Cardiovascular, Rhythm Management, Neuromodulation, and MedSurg (Endoscopy and Urology/Pelvic Health). The Cardiovascular segment offers technologies for diagnosing and treating heart and vascular conditions. The Rhythm Management segment focuses on devices for managing cardiac rhythm disorders. The Neuromodulation segment treats chronic pain and neurological disorders. The MedSurg segment encompasses Endoscopy and Urology/Pelvic Health, offering devices for gastrointestinal, pulmonary, and urological conditions.

Boston Scientific is a multinational organization with operations in over 100 countries and a workforce of more than 53,000 employees across six continents. Its global corporate headquarters is located in Marlborough, Massachusetts, USA. Regional headquarters are in Singapore and Paris, with major technology centers and manufacturing facilities in various locations. The United States is its largest market, representing approximately 60.96% of its total revenue in fiscal year 2024, while non-U.S. regions account for 39.04%. The company is actively expanding its presence in emerging markets, including Asia-Pacific and Latin America.

Boston Scientific maintains a strong brand reputation as a global leader and fierce competitor in the medical device industry, known for its meaningful innovation and operational excellence. The company is committed to transforming lives through innovative medical solutions and advancing science for life. However, in the past year, Boston Scientific's reputation was impacted by an event in September 2025 where the FDA flagged problems with two of its heart devices, which were tied to injuries and deaths.

Boston Scientific Corporation's ownership structure is primarily institutional, with institutional investors collectively owning approximately 82% to 90.93% of the company's shares. Insiders own about 0.17% to 5.71%, and retail investors own around 3.36% to 30.44%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Fmr Llc (Fidelity Investments), and State Street Corp. Promerica LP is noted as a significant individual shareholder, owning 54.64 million shares, representing 3.69% of the company.